Tag Archives: Trisomy 21

Race Against Time of Validation Study of Trisomy 21 Diagnostic Test II

Sequenom announced this week that they have entered into a supply agreement with Illumina for sequencing equipment and consumables. They will purchase the Illumina products for use in developing its non-invasive trisomy 21 test.

Sequenom plan to launch its SensiGene T21 test as a laboratory-developed test at the end of 2011 or in Q1 2012. The company also had previously disclosed that it had completed a validation study of its test on the Illumina HiSeq platform in 2,000 high-risk pregnancies, which will serve as the basis for the LDT.

It keeps exciting what GATC and Verinata are doing (resp. launching) in the meanwhile…

Race Against Time of Validation Study of Trisomy 21 Diagnostic Test I

Scientists at GATC Biotech AG and LifeCodexx AG have just begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing with IlluminaHiSeq 2000 technology. The test detects fetal trisomy 21 and is based on the sequencing cell-free fetal DNA from maternal blood.

At least 500 samples are required for the study and the launch of the prenatal diagnostic test onto the market is planned at the end of 2011. It keeps exciting what Sequenom and Verinata are doing in the meanwhile…

From Basic Research to Diagnostics

In 2008 two research groups have independently shown in proof of concept publications that trisomy 21 can be detected by high-throughput sequencing of cell free fetal DNA from the mother’s blood plasma with high specificity and high level of sensitivity (Fan et al., 2008; Chiu et al., 2008).

In short, Illumina reads are mapped to the reference human genome and by counting the reads that map to each chromosome the relative dosage of each chromosome is measured. In case of trisomy 21 or other aneuploidies the relative dosage of the affected chromosome is statistically overrepresented in the data set.

Within the last two months the companies Sequenom (Ehrich et al., 2011) and Verinata Health (Sehnert et al., 2011) both have published studies examining large test sets of patients. Both companies apply sequencing on GAIIx. The approaches mostly differ in normalization of sequencing data and bioinformatics analysis. Using a smart algorithm for normalizing the chromosome-counting data Verinata Health was able to classify 100 % correct all trisomy 21 and trisomy 18 samples in the test set (Sehnert et al., 2011).

While Sequenom recently finished the Clinical Validation Studies (GenomeWeb and Sequenom’s Web Page), Verinata Health is currently conducting a blinded clinical study to further demonstrate the diagnostic accuracy of their method (Sehnert et al., 2011)

Current screening methods are usually showing high false-positive results. Only invasive methods with high risk for mother and fetus provide definite genetic information about the fetus. The NGS based detection of fetal aneuploidy in high-risk-pregnancies is very promising from my point of view, as the method is non-invasive and is so far displaying high sensitivity and specificity.